Aeolus Pharmaceuticals to Present at OneMed Forum SF 2015 Conference
December 30, 2014 08:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 30, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Fiscal Year 2014 Financial Results
December 22, 2014 17:16 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 22, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Files International Patent Application for New Patent on AEOL 10150
December 03, 2014 08:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 03, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)Filing covers synthesis, formulation and pharmaceutical compositionCould significantly increase term of...
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
December 02, 2014 11:31 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - December 02, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Presentation of Efficacy Data for AEOL 10150 in Multiple Studies Showing Significant Survival Improvement and Tissue Protection After Radiation Exposure to the Lungs
October 20, 2014 07:00 ET
|
Aeolus Pharmaceuticals, Inc.
MISSION VIEJO, CA--(Marketwired - October 20, 2014) - • Data Reported in Presentation and Posters at the 60th Annual Meeting of the Radiation Research SocietyAeolus Pharmaceuticals, Inc.
(OTCQB: AOLS)...
Aeolus Announces Positive Results From Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
September 04, 2014 07:00 ET
|
Aeolus Pharmaceuticals, Inc.
MISSION VIEJO, CA--(Marketwired - September 04, 2014) - Findings reported by Dr. Tom MacVittie of the University of Maryland School of Medicine will be included in a pre-Emergency Use Authorization...
Aeolus Files Investigational New Drug Application With US Food and Drug Administration to Enable Initiation of Human Safety Studies for the Development of AEOL 10150 as a Medical Countermeasure Against Lung Damage From Radiation Exposure
August 20, 2014 13:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 20, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that it has filed an Investigational New Drug Application (IND) with the Division of...
Aeolus Announces Third Quarter Fiscal Year 2014 Financial Results and Achievements in Lung-ARS Development Program
August 15, 2014 07:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 15, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Additional Data Demonstrating Efficacy of AEOL 10150 as a Medical Countermeasure Against Exposure to Nerve Agents, Sulfur Mustard Gas and Nitrogen Mustard Gas
July 01, 2014 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 1, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data Presented at 8th Annual NIH Counteract Meeting in Denver
...
Aeolus Announces Publication of Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure
June 18, 2014 10:39 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 18, 2014) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced the publication of data from animal model studies demonstrating the efficacy of...